Local Application of Vancomycin in Spine Surgery Does Not Result in Increased Vancomycin-Resistant Bacteria-10-Year Data.


Journal

Spine deformity
ISSN: 2212-1358
Titre abrégé: Spine Deform
Pays: England
ID NLM: 101603979

Informations de publication

Date de publication:
09 2019
Historique:
received: 01 04 2018
revised: 19 01 2019
accepted: 26 01 2019
entrez: 10 9 2019
pubmed: 10 9 2019
medline: 28 4 2020
Statut: ppublish

Résumé

Case-control study. To analyze the microbial flora in surgical spine infections and their antibiotic resistance patterns across time and determine the correlation between vancomycin application in the wound and vancomycin-resistant microbes. Prior studies show a reduction in surgical site infections with intrawound vancomycin placement. No data are available on the potential negative effects of this intervention, in particular, whether there would be a resultant increase in vancomycin-resistant organisms or bacterial resistance profiles. All culture-positive surgical site infections at a single institution were analyzed from 2007 to 2017. Each bacterium was assessed independently for resistance patterns. The two-tailed Fisher exact test was used to determine the correlation between vancomycin application and the presence of vancomycin-resistant bacteria, polymicrobial infections, or gram-negative bacterial infections. One hundred and eight bacteria were isolated from 113 surgical site infections from 2007 to 2017. The most common organisms were staphylococcus with varying resistance patterns and Escherichia coli. Vancomycin-resistant Enterococcus faecium was isolated in three infections. Out of the 4,878 surgical cases from 2011 to 2017, vancomycin was placed in 48.3%, and no vancomycin in 51.7%. There were 33 infections (1.4%) in the vancomycin group and 20 infections (0.8%) in the no-vancomycin group (χ Topical vancomycin within the surgical site is not correlated with vancomycin-resistant bacteria. However, there was an increased incidence of gram-negative organisms in infections after vancomycin application in the wound versus no vancomycin. Continued surveillance with prospectively collected randomized data is necessary to better understand bacterial evolution against current antimicrobial techniques. Level III.

Sections du résumé

STUDY DESIGN
Case-control study.
OBJECTIVES
To analyze the microbial flora in surgical spine infections and their antibiotic resistance patterns across time and determine the correlation between vancomycin application in the wound and vancomycin-resistant microbes.
SUMMARY OF BACKGROUND DATA
Prior studies show a reduction in surgical site infections with intrawound vancomycin placement. No data are available on the potential negative effects of this intervention, in particular, whether there would be a resultant increase in vancomycin-resistant organisms or bacterial resistance profiles.
METHODS
All culture-positive surgical site infections at a single institution were analyzed from 2007 to 2017. Each bacterium was assessed independently for resistance patterns. The two-tailed Fisher exact test was used to determine the correlation between vancomycin application and the presence of vancomycin-resistant bacteria, polymicrobial infections, or gram-negative bacterial infections.
RESULTS
One hundred and eight bacteria were isolated from 113 surgical site infections from 2007 to 2017. The most common organisms were staphylococcus with varying resistance patterns and Escherichia coli. Vancomycin-resistant Enterococcus faecium was isolated in three infections. Out of the 4,878 surgical cases from 2011 to 2017, vancomycin was placed in 48.3%, and no vancomycin in 51.7%. There were 33 infections (1.4%) in the vancomycin group and 20 infections (0.8%) in the no-vancomycin group (χ
CONCLUSIONS
Topical vancomycin within the surgical site is not correlated with vancomycin-resistant bacteria. However, there was an increased incidence of gram-negative organisms in infections after vancomycin application in the wound versus no vancomycin. Continued surveillance with prospectively collected randomized data is necessary to better understand bacterial evolution against current antimicrobial techniques.
LEVEL OF EVIDENCE
Level III.

Identifiants

pubmed: 31495468
pii: S2212-134X(19)30021-8
doi: 10.1016/j.jspd.2019.01.005
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Vancomycin 6Q205EH1VU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

696-701

Informations de copyright

Copyright © 2019 Scoliosis Research Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Krishn Khanna (K)

Department of Orthopaedic Surgery, University of California, San Francisco, 500 Parnassus Ave, MU320W, San Francisco, CA 94143, USA.

Frank Valone (F)

California Pacific Orthopaedics, Spine Institute, 3838 California Street, Suite 715, San Francisco, CA 94118, USA.

Alexander Tenorio (A)

Department of Orthopaedic Surgery, University of California, San Francisco, 500 Parnassus Ave, MU320W, San Francisco, CA 94143, USA.

Trevor Grace (T)

Department of Orthopaedic Surgery, University of California, San Francisco, 500 Parnassus Ave, MU320W, San Francisco, CA 94143, USA.

Shane Burch (S)

Department of Orthopaedic Surgery, University of California, San Francisco, 500 Parnassus Ave, MU320W, San Francisco, CA 94143, USA.

Sigurd Berven (S)

Department of Orthopaedic Surgery, University of California, San Francisco, 500 Parnassus Ave, MU320W, San Francisco, CA 94143, USA.

Bobby Tay (B)

Department of Orthopaedic Surgery, University of California, San Francisco, 500 Parnassus Ave, MU320W, San Francisco, CA 94143, USA.

Vedat Deviren (V)

Department of Orthopaedic Surgery, University of California, San Francisco, 500 Parnassus Ave, MU320W, San Francisco, CA 94143, USA.

Serena S Hu (SS)

Department of Orthopaedic Surgery, Stanford University, 450 Broadway St., Redwood City, CA 94063, USA. Electronic address: shu3@stanford.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH